Diversified Healthcare Trust 5.625% Senior Notes due 2042 (DHCNI)

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I would begin by remembering that this is a senior note, not common equity, so the central question is creditworthiness, not earnings multiples. The issuer’s filed figures are not reassuring. In FY2025, the year ended 2025-12-31, revenue was $1.5B but net income was -$285.9M and diluted EPS -$1.19. FY2024 net income was -$370.3M and diluted EPS -$1.55, while FY2023 net income was -$293.6M and diluted EPS -$1.23. The recent trend remains negative: in fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$43.3M and diluted EPS -$0.18; in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $365.4M, net income -$37.4M, and diluted EPS -$0.16. The loss is smaller than fiscal Q2 2025’s -$91.6M net income, but it is still a loss. I see no evidence of a durable moat; revenue scale is not profit. FairStock shows P/E, P/B, ROE and ROCE as N/A, with a FairStock Score of N/A, and the Lynch category is none because the company has lost money in each of the last four years. At the $17.29 close on 2026-10-16, inside the 52-week range of $15.85-$19.10, there is no earnings-based valuation to call the note cheap. Revenue is not clearly growing—fiscal Q2 2026 revenue of $365.4M compares with $382.7M in fiscal Q2 2025. This is a weak, loss-making credit; the 5.625% coupon is only as good as the issuer’s future cash flow.

In plain English: This is a bond-like security tied to a real estate company that has been losing money. The business looks weak: filed figures show net losses in fiscal 2023, fiscal 2024, fiscal 2025, and the first two quarters of 2026. At $17.29, the price is within its 52-week range, but there are no profits and no usable valuation measures, so it is not possible to say it is cheap or expensive from the data.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-16 close · note generated 2026-10-20 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer